Follow
Andreas Schlicker
Andreas Schlicker
Research Scientist Bioinformatics, Bayer Pharma AG
Verified email at bayer.com
Title
Cited by
Cited by
Year
The consensus molecular subtypes of colorectal cancer
J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ...
Nature medicine 21 (11), 1350-1356, 2015
36552015
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118-122, 2014
8002014
A new measure for functional similarity of gene products based on Gene Ontology
A Schlicker, FS Domingues, J Rahnenführer, T Lengauer
BMC bioinformatics 7, 1-16, 2006
7982006
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling
S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ...
Cell 151 (5), 937-950, 2012
4442012
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition
P Roepman, A Schlicker, J Tabernero, I Majewski, S Tian, V Moreno, ...
International journal of cancer 134 (3), 552-562, 2014
3572014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ...
Cell reports 7 (1), 86-93, 2014
3152014
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
A Schlicker, G Beran, CM Chresta, G McWalter, A Pritchard, S Weston, ...
BMC medical genomics 5 (1), 1-15, 2012
2632012
The implications of alternative splicing in the ENCODE protein complement
ML Tress, PL Martelli, A Frankish, GA Reeves, JJ Wesselink, C Yeats, ...
Proceedings of the National Academy of Sciences 104 (13), 5495-5500, 2007
2432007
ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy
FH Groenendijk, J de Jong, EEF van de Putte, M Michaut, A Schlicker, ...
European urology 69 (3), 384-388, 2016
1882016
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ...
Scientific reports 6 (1), 1-13, 2016
1632016
Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
AM Sieuwerts, S Willis, MB Burns, MP Look, MEMV Gelder, A Schlicker, ...
Hormones and Cancer 5, 405-413, 2014
1512014
Improving disease gene prioritization using the semantic similarity of Gene Ontology terms
A Schlicker, T Lengauer, M Albrecht
Bioinformatics 26 (18), i561-i567, 2010
1372010
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
L Henneman, MH van Miltenburg, EM Michalak, TM Braumuller, ...
Proceedings of the National Academy of Sciences 112 (27), 8409-8414, 2015
1272015
FunSimMat: a comprehensive functional similarity database
A Schlicker, M Albrecht
Nucleic acids research 36 (suppl_1), D434-D439, 2007
1102007
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer ModelsAntitumor …
AM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ...
Molecular cancer therapeutics 19 (1), 26-38, 2020
1022020
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
C Welsch, FS Domingues, S Susser, I Antes, C Hartmann, G Mayr, ...
Genome biology 9, 1-18, 2008
982008
A vulnerability of a subset of colon cancers with potential clinical utility
L Vecchione, V Gambino, J Raaijmakers, A Schlicker, A Fumagalli, ...
Cell 165 (2), 317-330, 2016
942016
Computational analysis of human protein interaction networks
F Ramirez, A Schlicker, Y Assenov, T Lengauer, M Albrecht
Proteomics 7 (15), 2541-2552, 2007
892007
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid TumorsATR Inhibitor BAY 1895344 in Advanced …
TA Yap, DSP Tan, A Terbuch, R Caldwell, C Guo, BC Goh, V Heong, ...
Cancer discovery 11 (1), 80-91, 2021
802021
Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.
R Dienstmann, J Guinney, M Delorenzi, A De Reynies, P Roepman, ...
Journal of Clinical Oncology 32 (15_suppl), 3511-3511, 2014
722014
The system can't perform the operation now. Try again later.
Articles 1–20